Multigene testing panels reveal pathogenic variants in sporadic breast cancer patients in northern China

被引:1
|
作者
Liu, Yinfeng [1 ]
Zheng, Jie [1 ]
Xu, Yue [2 ]
Lv, Ji [1 ]
Wu, Zizheng [1 ]
Feng, Kai [1 ]
Liu, Jiani [1 ]
Yan, Weitao [1 ]
Wei, Liguang [1 ]
Zhao, Jiangman [2 ]
Jiang, Lisha [2 ]
Han, Meng [1 ]
机构
[1] First Hosp Qinhuangdao, Breast Dis Diag & Treatment Ctr, Qinhuangdao, Hebei, Peoples R China
[2] Shanghai Biotecan Pharmaceut Co Ltd, Shanghai, Peoples R China
关键词
breast cancer; multi-gene panels; rare genetic variants; in silico protein modeling; pathogenic/likely pathogenic variants; GERMLINE MUTATIONS; ASSOCIATION; BRCA1;
D O I
10.3389/fgene.2023.1271710
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Breast cancer, the most prevalent malignancy in women worldwide, presents diverse onset patterns and genetic backgrounds. This study aims to examine the genetic landscape and clinical implications of rare mutations in Chinese breast cancer patients.Methods: Clinical data from 253 patients, including sporadic and familial cases, were analyzed. Comprehensive genomic profiling was performed, categorizing identified rare variants according to the American College of Medical Genetics (ACMG) guidelines. In silico protein modeling was used to analyze potentially pathogenic variants' impact on protein structure and function.Results: We detected 421 rare variants across patients. The most frequently mutated genes were ALK (22.2%), BARD1 (15.6%), and BRCA2 (15.0%). ACMG classification identified 7% of patients harboring Pathogenic/Likely Pathogenic (P/LP) variants, with one case displaying a pathogenic BRCA1 mutation linked to triple-negative breast cancer (TNBC). Also identified were two pathogenic MUTYH variants, previously associated with colon cancer but increasingly implicated in breast cancer. Variants of uncertain significance (VUS) were identified in 112 patients, with PTEN c.C804A showing the highest frequency. The role of these variants in sporadic breast cancer oncogenesis was suggested. In-depth exploration of previously unreported variants led to the identification of three potential pathogenic variants: ATM c.C8573T, MSH3 c.A2723T, and CDKN1C c.C221T. Their predicted impact on protein structure and stability suggests a functional role in cancer development.Conclusion: This study reveals a comprehensive overview of the genetic variants landscape in Chinese breast cancer patients, highlighting the prevalence and potential implications of rare variants. We emphasize the value of comprehensive genomic profiling in breast cancer management and the necessity of continuous research into understanding the functional impacts of these variants.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Pathogenic Germline Variants in Patients With Metastatic Breast Cancer
    Stuttgen, Kelsey
    Croessmann, Sarah
    Fetting, John
    Stearns, Vered
    Nunes, Raquel
    Connolly, Roisin M.
    Park, Ben Ho
    JAMA ONCOLOGY, 2019, 5 (10) : 1506 - 1508
  • [22] Pathogenic Germline Variants in Patients With Metaplastic Breast Cancer
    Demarest, Kaitlin
    Anantharajah, Arravinth
    Maxwell, Kara N.
    Rohanizadegan, Mersedeh
    Bradbury, Angela
    Nathanson, Katherine L.
    Mccarthy, Anne Marie
    Domchek, Susan M.
    Nayak, Anupma
    Shah, Payal D.
    JAMA NETWORK OPEN, 2025, 8 (02)
  • [23] Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
    Infante, Mar
    Arranz-Ledo, Monica
    Lastra, Enrique
    Abella, Luis Enrique
    Ferreira, Raquel
    Orozco, Marta
    Hernandez, Lara
    Martinez, Noemi
    Duran, Mercedes
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [24] Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing
    Chang, Jenny
    Seng, Sirivan
    Yoo, June
    Equivel, Pamela
    Lum, Sharon S.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (10) : 3389 - 3396
  • [25] Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing
    Jenny Chang
    Sirivan Seng
    June Yoo
    Pamela Equivel
    Sharon S. Lum
    Annals of Surgical Oncology, 2019, 26 : 3389 - 3396
  • [26] Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker
    Jing, Feng
    Jun, Lu
    Yong, Zhang
    Wang, Yuping
    Fei, Xie
    Zhang, Jicai
    Hu, Lihua
    ONCOLOGY, 2008, 75 (1-2) : 60 - 66
  • [27] Multigene panel testing for breast cancer patients at high risk for hereditary cancer
    Shin, H-C.
    Yoo, T-K.
    Lee, E.
    Kee, H-B.
    Han, J.
    Kim, Y.
    Moon, H-G.
    Noh, D-Y.
    Han, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer
    Ryu, Jin-Sun
    Lee, Hye-Young
    Cho, Eun Hae
    Yoon, Kyong-Ah
    Kim, Min-Kyeong
    Joo, Jungnam
    Lee, Eun-Sook
    Kang, Han-Sung
    Lee, Seeyoun
    Lee, Dong Ock
    Lim, Myong Cheol
    Kong, Sun-Young
    CANCER SCIENCE, 2020, 111 (10) : 3912 - 3925
  • [29] Comparing actionable results for breast and colorectal cancer patients across multigene panels.
    Fulk, Kelly
    Espenschied, Carin
    Profato, Jessica
    Reineke, Patrick
    LaDuca, Holly
    Smith, Robina
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Multigene panel testing results in patients with multiple breast cancer primaries
    Corredor, Jessica
    Woodson, Ashley H.
    Gutierrez Barrera, Angelica
    Arun, Banu
    BREAST JOURNAL, 2020, 26 (07): : 1337 - 1342